Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$8.81 -1.5%	$12.13	$7.80 ▼ $28.09	$487.55M	N/A	587,927 shs	1.05 million shs
GNFT GENFIT	$3.84 +6.4%	$4.11	$2.55 ▼ $6.42	$180.49M	1.15	10,470 shs	6,888 shs
IMNM Immunome	$8.79 +1.3%	$8.59	$5.15 ▼ $16.81	$755.27M	1.94	900,176 shs	628,148 shs
PRAX Praxis Precision Medicines	$44.04 +1.6%	$39.58	$26.70 ▼ $91.83	$882.59M	2.6	376,166 shs	183,030 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-1.45%	-6.57%	-11.72%	-34.25%	+880,999,900.00%
GNFT GENFIT	+1.21%	-4.38%	-10.36%	+5.96%	+2.40%
IMNM Immunome	+1.27%	-0.45%	+2.21%	+25.75%	-26.93%
PRAX Praxis Precision Medicines	+1.64%	+2.49%	+21.99%	+13.92%	+8.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	2.203 of 5 stars	3.5	0.0	1.6	0.8	1.3
GNFT GENFIT	2.4229 of 5 stars	3.5	5.0	2.5	0.0	0.0
IMNM Immunome	1.6139 of 5 stars	3.5	0.0	2.2	2.5	0.0
PRAX Praxis Precision Medicines	3.1987 of 5 stars	4.4	2.0	3.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	261.62% Upside
GNFT GENFIT	3.00	Buy	$13.00	238.54% Upside
IMNM Immunome	3.00	Buy	$23.33	165.45% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$109.90	149.55% Upside

Current Analyst Ratings Breakdown

Latest GNFT, PRAX, IMNM, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/5/2025	PRAX Praxis Precision Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$26.00 ➝ $28.00
5/5/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/1/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
GNFT GENFIT	$76.77M	2.50	$0.07 per share	51.61	$1.50 per share	2.56
IMNM Immunome	$9.04M	84.60	N/A	N/A	$2.27 per share	3.87
PRAX Praxis Precision Medicines	$8.55M	104.92	N/A	N/A	$23.90 per share	1.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)

Latest GNFT, PRAX, IMNM, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	24.62	24.62
GNFT GENFIT	0.08	1.23	1.23
IMNM Immunome	N/A	10.49	10.49
PRAX Praxis Precision Medicines	N/A	8.44	8.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
GNFT GENFIT	2.24%
IMNM Immunome	44.58%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
GNFT GENFIT	4.20%
IMNM Immunome	8.60%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	46.08 million	N/A
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
IMNM Immunome	40	87.01 million	79.53 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable

GNFT, PRAX, IMNM, and BCAX Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Sells 51,682 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

June 14, 2025 | marketbeat.com

Needham & Company LLC Reaffirms Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX)

June 12, 2025 | marketbeat.com

Bank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

June 12, 2025 | marketbeat.com

Former head trader of Denver-based investing company pleads guilty to insider trading

June 9, 2025 | finance.yahoo.com

Weston man pleads guilty to insider trading offense that made him $220K

June 8, 2025 | stamfordadvocate.comS

Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 7.6% - Here's Why

June 5, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 4, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Wellington Management Group LLP

June 4, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Holdings Reduced by Squarepoint Ops LLC

June 4, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

June 3, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at Oppenheimer

June 2, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial Markets

June 1, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 5.6% - Should You Sell?

May 31, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading 4.3% Higher - Should You Buy?

May 30, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

May 28, 2025 | marketbeat.com

9,948 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Purchased by Woodline Partners LP

May 28, 2025 | marketbeat.com

Voloridge Investment Management LLC Buys 40,875 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

May 27, 2025 | marketbeat.com

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 7, 2025 | benzinga.com

Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation

May 7, 2025 | msn.com

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

May 5, 2025 | finance.yahoo.com

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

May 4, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT, PRAX, IMNM, and BCAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$8.81 -0.13 (-1.45%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$8.95 +0.14 (+1.59%)

As of 06/26/2025 07:41 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

GENFIT NASDAQ:GNFT

$3.80 +0.19 (+5.12%)

As of 06/26/2025 03:59 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Immunome NASDAQ:IMNM

$8.79 +0.11 (+1.27%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$8.79 0.00 (0.00%)

As of 06/26/2025 04:23 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Praxis Precision Medicines NASDAQ:PRAX

$44.04 +0.71 (+1.64%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$44.02 -0.02 (-0.04%)

As of 04:00 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time